What is Ribometrix?
Headquartered in the Research Triangle Park, Ribometrix is fundamentally redefining the parameters of drug discovery. The company specializes in the development of small molecule therapeutics designed to bind to specific RNA structures, thereby correcting the production of disease-causing proteins. This approach offers a distinct advantage over conventional protein-targeting methods, as it allows for the modulation of targets that were historically considered inaccessible. By integrating innovative RNA-targeting technologies with established drug development workflows, Ribometrix is building a robust pipeline aimed at treating a wide spectrum of complex human diseases. The firm's strategic focus on the intersection of genomics and chemistry places it at the vanguard of precision medicine, providing a scalable platform for future therapeutic breakthroughs.
How much funding has Ribometrix raised?
Ribometrix has raised a total of $45.3M across 3 funding rounds:
Angel/Seed
$7.5M
Series A
$30M
Other Financing Round
$7.8M
Angel/Seed (2017): $7.5M with participation from MP Healthcare Venture Management, Hatteras Venture Partners, Dementia Discovery Fund, and SV Health Investors
Series A (2018): $30M led by M Ventures
Other Financing Round (2019): $7.8M supported by Dementia Discovery Fund and Illumina Ventures
Key Investors in Ribometrix
M Ventures
M Ventures is the strategic, corporate venture capital arm of Merck, investing globally in transformational ideas and early-stage technologies that impact core business areas.
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm focused on building transformative companies in the biotech, MedTech, and HealthTech sectors with over 25 years of experience.
SV Health Investors
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, providing capital and sector expertise from early growth through scale.
What's next for Ribometrix?
With the infusion of capital from its latest financing rounds, Ribometrix is well-positioned to accelerate its transition from a discovery-focused entity to a clinical-stage powerhouse. The strategic roadmap likely involves the expansion of its internal R&D capabilities and the deepening of its collaborative efforts with industry partners to validate its lead candidates. As the company matures, the focus will shift toward optimizing its proprietary platform to increase the throughput of its drug discovery engine. Given the high-stakes nature of RNA modulation, Ribometrix will likely prioritize the advancement of its most promising assets into human trials, while simultaneously exploring new therapeutic indications that leverage its unique technological edge in the life sciences sector.
See full Ribometrix company page
